-- FireFox Gold (FFOX.V) 周四公布了其位于芬兰拉普兰地区全资拥有的 Sarvi 金矿项目 2025 年勘探钻探计划剩余三个钻孔的钻探结果。 该公司表示，此次小型勘探钻探计划的目标是勘探位于项目区西侧 Keulakko 矿权区内，穿过离散磁异常高值区和磁梯度区的区域性构造。 该公司还表示，25SA002 号钻孔是沿东北-西南方向进行的一系列钻探的一部分，旨在测试位于 GTK 钻孔以东 250 至 500 米处的构造-磁异常走廊。该公司指出，25SA002 号钻孔在井下 51.5 米处发现了一个狭窄的金矿化层段，厚度为 1.0 米，金品位为 2.68 克/吨。 该公司补充道，钻孔25SA004和25SA005位于钻孔25SA003以东约480米处。该公司表示，这些钻孔沿西南方向呈围栏状钻探，目标是已推断的区域性构造。该公司还补充说，钻孔25SA005钻遇了一个低品位金矿段。 该公司计划在今年晚些时候开展后续的勘探钻探工作，包括更多的地表取样、详细的地球物理勘测和钻探。 该公司股票在多伦多证券交易所创业板的最新交易价格为0.64美元，与前一日持平。
Related Articles
Research
Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ADBE
Treasury
US Treasury Yields Edge Up Pre-Bell as Iran's Hormuz Offer Delinks Deal With Nuclear Talks
US Markets
Organon Agrees to Be Acquired by Sun Pharmaceutical in $11.75 Billion Deal
Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.
$OGN